HomeQuestion
Is there a clinically significant increased risk of venous thromboembolism with the use of fulvestrant for metastatic HR+ breast cancer?
1 Answers
Mednet Member
Medical Oncology · Icahn School of Medicine at Mount Sinai
The reason for VTE? Post-operative, trauma, hypercoagulability due to having cancer or its treatment, hereditary hypercoagulability, or idiopathic? I am going to assume that the VTE was self-limited and treated with a course of anticoagulation. Does fulvestrant cause VTE? Ideally, a randomized place...